Business News

Roche above approved by the FDA for diabetic retinopathy

Marvin Samuel Tolentino Pineda / Istoc Vitty Images

  • ROCHE (OTCQX: RHHBY) announced that the American FDA had approved ARRAVIMO 100 mg / ml for the treatment of diabetic retinopathy.
  • Approval allows us the retina specialists to offer ARAVIMO to DR patients who have already responded to at least two anti-VEGF injections.

Related Articles

Leave a Reply

Your email address will not be published. Required fields are marked *

Back to top button